JP2015513370A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513370A5
JP2015513370A5 JP2015500570A JP2015500570A JP2015513370A5 JP 2015513370 A5 JP2015513370 A5 JP 2015513370A5 JP 2015500570 A JP2015500570 A JP 2015500570A JP 2015500570 A JP2015500570 A JP 2015500570A JP 2015513370 A5 JP2015513370 A5 JP 2015513370A5
Authority
JP
Japan
Prior art keywords
brain injury
patient
post
isoform
gfap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015500570A
Other languages
English (en)
Japanese (ja)
Other versions
JP6392202B2 (ja
JP2015513370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/031012 external-priority patent/WO2013138509A1/en
Publication of JP2015513370A publication Critical patent/JP2015513370A/ja
Publication of JP2015513370A5 publication Critical patent/JP2015513370A5/ja
Application granted granted Critical
Publication of JP6392202B2 publication Critical patent/JP6392202B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015500570A 2012-03-13 2013-03-13 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質 Active JP6392202B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610034P 2012-03-13 2012-03-13
US61/610,034 2012-03-13
PCT/US2013/031012 WO2013138509A1 (en) 2012-03-13 2013-03-13 Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration

Publications (3)

Publication Number Publication Date
JP2015513370A JP2015513370A (ja) 2015-05-11
JP2015513370A5 true JP2015513370A5 (https=) 2016-05-12
JP6392202B2 JP6392202B2 (ja) 2018-09-19

Family

ID=49161784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500570A Active JP6392202B2 (ja) 2012-03-13 2013-03-13 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質

Country Status (5)

Country Link
US (4) US9709573B2 (https=)
EP (1) EP2825893A4 (https=)
JP (1) JP6392202B2 (https=)
HK (1) HK1206425A1 (https=)
WO (1) WO2013138509A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20160125454A1 (en) * 2014-11-04 2016-05-05 Yahoo! Inc. Systems and methods for managing advertising campaigns
JP2018510359A (ja) * 2015-02-05 2018-04-12 イミューンアレイ ユーエスエイ インコーポレイテッド 脳損傷または神経変性を診断するための方法および組成物
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
WO2017065127A1 (ja) * 2015-10-14 2017-04-20 公立大学法人横浜市立大学 腎癌薬物療法の効果判定のための血中バイオマーカー
WO2018030252A1 (ja) * 2016-08-09 2018-02-15 大塚製薬株式会社 尿バイオマーカーを用いたアルツハイマー病の診断補助方法
KR101834724B1 (ko) 2016-08-11 2018-03-06 한림대학교 산학협력단 시트룰린화 미엘린 염기성 단백질에 대한 모노클론 항체 및 이를 이용한 신경 퇴행성 질환 진단 킷트
US11402379B2 (en) 2016-09-09 2022-08-02 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating autoimmune GFAP astrocytopathy
US20180280503A1 (en) * 2017-04-04 2018-10-04 The Johns Hopkins University Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
WO2018217792A1 (en) * 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
JP6344783B1 (ja) * 2017-06-21 2018-06-20 エフビートライアングル株式会社 ガス分析に基づく評価システム
WO2020037311A1 (en) * 2018-08-17 2020-02-20 University Of Florida Research Foundation, Inc. Protein and peptide biomarkers for traumatic injury to the central nervous system
US20220146527A1 (en) * 2019-09-17 2022-05-12 Chang Gung University Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms
US11835519B2 (en) 2019-12-17 2023-12-05 Euroimmun Medizinische Labordiagnostika Ag Autoantibodies to Septin-7 and diagnosis of neurological disease
CN110988207B (zh) * 2019-12-17 2021-03-23 厦门历思科技服务有限公司 基于人体摄入物质检测的监测方法
EP3940383A1 (en) * 2020-07-16 2022-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the outcome of patients having acute ischemic stroke
US11940450B2 (en) 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
CN120712049A (zh) 2022-12-15 2025-09-26 阿达普提克斯生物科学公司 用于分析物检测的系统和方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263063C (en) 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20030077590A1 (en) 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
WO2002024867A2 (en) 2000-09-22 2002-03-28 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
US6884591B2 (en) 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
JP2005522669A (ja) 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US20030040660A1 (en) 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
US20070098728A1 (en) 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
CA2518187A1 (en) 2003-03-07 2004-09-16 London Health Sciences Centre Reseach, Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
EP2207033B1 (en) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US7985555B2 (en) 2004-06-25 2011-07-26 Washington University Markers for brain damage
AU2005314231A1 (en) 2004-12-04 2006-06-15 The Regents Of The University Of California Protein subcellular localization assays using split fluorescent proteins
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) * 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
ES2443042T3 (es) 2006-10-16 2014-02-17 Bayer Intellectual Property Gmbh LTBP2 como biomarcador, diana terapéutica y diagnóstica
JP2008157905A (ja) 2006-12-25 2008-07-10 Hectef Standard Reference Center Foundation 添加法による生体試料中蛋白・ペプチドの定量方法
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
JP5305259B2 (ja) * 2007-12-25 2013-10-02 地方独立行政法人東京都健康長寿医療センター 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途
CN101983337A (zh) 2008-02-04 2011-03-02 班扬生物标记公司 用于诊断或治疗脑损伤的方法
EP2294425B1 (en) 2008-05-23 2013-05-22 The Johns Hopkins University Biomarkers for myocardial ischemia
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
US8119694B2 (en) 2008-08-15 2012-02-21 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
WO2010048388A1 (en) * 2008-10-22 2010-04-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunoassays for citrullinated proteins
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
EP3355059A3 (en) 2009-06-19 2018-09-26 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011032155A2 (en) * 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
EP2628013B1 (en) 2010-10-14 2019-06-12 The Johns Hopkins University Biomarkers of brain injury
BR112013019380A2 (pt) 2011-01-28 2019-10-01 Immunosciences Lab Inc método para detecção de permeabilidade da barreira hematoencefálica, e intestinal e materiais de teste da mesma
JP2014518624A (ja) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー ニューログラニン診断キットのためのアッセイ試薬
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
US9709573B2 (en) * 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20150119273A1 (en) 2012-05-16 2015-04-30 Trustees Of Boston University Chronic Traumatic Encephalopathy in Blast-Exposed Individuals
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
WO2015157390A1 (en) 2014-04-08 2015-10-15 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
WO2016055148A2 (en) 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury
EP3029466A1 (en) 2014-12-03 2016-06-08 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Methods for differentiating ischemic stroke from hemorrhagic stroke
EP3322988A1 (en) 2015-07-13 2018-05-23 University of Geneva Biomarker panels for brain injury complications

Similar Documents

Publication Publication Date Title
JP2015513370A5 (https=)
JP2013545087A5 (https=)
Miller et al. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis
JP2017524130A5 (https=)
Palavra et al. New markers of early cardiovascular risk in multiple sclerosis patients: oxidized‐LDL correlates with clinical staging
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
JP2010524432A5 (https=)
JP2017510622A (ja) 筋萎縮を予測するバイオマーカー、方法および使用
JP2014506244A5 (https=)
JP2013502569A5 (https=)
JP2012198248A5 (https=)
KR101972602B1 (ko) 신경 질환의 예후를 위한 ｈｍｇｂ1 및 항-ｈｍｇｂ1 항체
JP2017500562A5 (https=)
JP2014506244A (ja) 自閉症の診断、治療におけるバイオマーカーおよびその使用
JP2014506244A6 (ja) 自閉症の診断、治療におけるバイオマーカーおよびその使用
El-Sadek et al. Arginine dimethylation products in pediatric patients with chronic kidney disease
JP2024096748A (ja) アルファ－シヌクレイン病のアッセイ、方法、及び治療
Gmitterová et al. DNA versus RNA oxidation in Parkinson’s disease: Which is more important?
JP2014505254A5 (https=)
Papuć et al. Humoral response against glial derived antigens in Parkinson's disease
Kołakowska et al. Correlation of Salusin Beta with hs-CRP and ADMA in Hypertensive Children and Adolescents
Zhou et al. Blood‐based biomarkers for Alzheimer's disease in Down syndrome: a systematic review and meta‐analysis
WO2024040225A2 (en) Diagnosis and treatment of acute kidney injury
JP2012526543A5 (https=)
JP2017524933A (ja) 川崎病の診断及び治療